Investment and Company Research
Opportunity Research
MICROCAP HOT TOPICS
 

June 13, 2013

PLANDAÍ BIOTECHNOLOGY POSITIONS ITSELF IN WAR AGAINST CHOLESTEROL

Ten years ago, consumers were very anxious about their cholesterol levels. Moreover, there was a great deal of confusion regarding the difference between “good” cholesterol and “bad” cholesterol.  Still, relationship between high cholesterol levels and potential heart issues prompted a number of studies targeting the reduction of bad cholesterol, including those using green tea. 

Considering the higher bioavailability of the Plandaí Biotechnology Inc. (OTCQB - PLPL - $0.51 - Spec Buy) offerings, there will likely be future trials using Plandaí’s products in order to maximize consumption and efficacy of the key catechins. Plandaí develops highly bioavailable, phytonutrient rich extracts that include known anti-oxidants, such as EGCG found in green tea, which it plans to utilize to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions.

Recently published studies have indicated that groups who consumed high amounts of green tea had reduced levels of “bad” cholesterol.  In fact, the participants who consumed green tea had demonstrated a 7.2 milligrams per deciliter (mg/dL) reduction in total cholesterol levels compared to the participants who did not consume green tea. These participants also had their “bad” cholesterol levels dropped by 2.2 mg/dL.

Another study, which ran 20 trials spanning anywhere from 3 to 20 weeks, showed a marked reduction in low-density lipoprotein (LDL) levels (ie.- bad cholesterol). Specifically, the participants showed a five to six point reduction in their levels. The common denominator in both trials is the correlation between green tea consumption and cholesterol reduction, along with overall wellness. Green tea contains catechin polyphenols, specifically the powerful antioxidant, epigallocatechin gallate (EGCG).  Unfortunately, green tea polyphenols, including EGCG, are notorious for their low bioavailability or ability to be absorbed into the blood stream.

Today, consumers are extremely focused on overall wellness, health, and the use of organically-based offerings that can aid in the prevention of a multitude of diseases and conditions. To that end, a number of manufacturers that produce green tea-based products are still seeking products that demonstrate the greatest degree of efficacy in treating and ensuring overall wellness.  Considering that Plandaí offers Phytofare™ Catechin Complex, which is processed to deliver a natural, antioxidant-rich product that contains the full range of green tea catechins at a bioavailability level many times that of other products available on the market, the Company’s flagship product could emerge as consumers’ cholesterol lowering product of choice.

For more information, refer to our previous PLPL Reports, Updates and Hot Topics by visiting www.GoldmanResearch.com

Senior Analyst: Robert Goldman
Rob Goldman has over 20 years of investment and company research experience as a senior research analyst and as a portfolio and mutual fund manager. During his tenure as a sell side analyst, Rob was a senior member of Piper Jaffray's Technology and Communications teams. Prior to joining Piper, Rob led Josephthal & Co.'s Washington-based Emerging Growth Research Group. In addition to his sell-side experience Rob served as Chief Investment Officer of a boutique investment management firm and Blue and White Investment Management, where he managed Small Cap Growth portfolios and The Blue and White Fund.

Analyst Certification
I, Robert Goldman, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report. 

Disclaimer
 This Opportunity Research Hot Topics article was prepared for informational purposes only. Goldman Small Cap Research, (a division of Two Triangle Consulting Group, LLC) produces research via two formats: Goldman Select Research and Goldman Opportunity Research. The Select product reflects the Firm’s internally generated stock ideas while the Opportunity product reflects sponsored research reports. It is important to note that while we may track performance separately, we utilize the same coverage criteria in determining coverage of all stocks in both research formats. While stocks in the Opportunity format may have a higher risk profile, they typically offer greater upside as well. Since April 2012, Goldman Small Cap Research has been compensated $500 per article by a third party.  All information contained in this report was provided by the Company or derived from GSCR due diligence. Our analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests, retain editorial control, and ensure independence. Analysts are compensated on a per report basis and not on the basis of his/her recommendations.

The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, or other firms. Goldman Small Cap Research relied solely upon information provided by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such information and the opinions expressed are subject to change without notice. A Goldman Small Cap Research report, update, article, or note is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed.

This publication does not take into account the investment objectives, financial situation, or particular needs of any particular person. This report does not provide all information material to an investor’s decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither Goldman Small Cap Research, nor its parent, is registered as a securities broker-dealer or an investment adviser with FINRA, the U.S. Securities and Exchange Commission or with any state securities regulatory authority.

ALL INFORMATION IN THIS REPORT IS PROVIDED “AS IS” WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.